Pazopanib hydrochloride.: Oncolytic, angiogenesis inhibitor, VEGFR-2 tyrosine kinase inhibitor

Tumor progression requires angiogenesis and targeting this process is a particularly attractive anticancer strategy. Vascular endothelial growth factor (VEGF) is a key mediator of neovascularization and research has intensely focused on interfering with the V'EGF/VEGF receptor (VEGFR) signaling system in order to modulate angiogenesis. The development of small-molecule tyrosine kinase inhibitors targeting VEGFRs as potential antiangiogenic agents has progressed in recent years, with more than 30 VEGFR inhibitors under active development for the treatment of cancer. The indazolylpyrimidine pazopanib hydrochloride (786034, GW-786034) is one such pan-VEGFR inhibitor that has shown potent preclinical and clinical antitumor activity. It is undergoing phase II development as an antiangiogenic antitumor agent.